Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer

Area of Science:

• Oncology
• Medical Imaging
• Biotechnology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with poor prognosis.
• Early detection of PDAC remains a significant challenge due to the lack of efficient diagnostic technologies.

Purpose of the Study:

• To evaluate the potential of an RGD-NGR heterodimer labeled with a PET isotope for early detection of PDAC.
• To compare the efficacy of the RGD-NGR tracer against monomeric counterparts and standard imaging agents.

Main Methods:

• PET imaging studies in mouse models bearing subcutaneous tumors and autochthonous PDAC.
• Ex vivo biodistribution studies.
• Comparison with [18F]F-FDG PET imaging.
• Histopathological analysis (H&E staining) and immunofluorescence staining for receptor confirmation.

Main Results:

• The RGD-NGR tracer demonstrated superior in vivo performance compared to monomeric versions in a subcutaneous tumor model.
• The tracer successfully detected both pre-malignant and malignant pancreatic lesions in autochthonous mouse models.
• The RGD-NGR heterodimer showed better imaging of spontaneous PDAC than [18F]F-FDG.
• Integrin αVβ3 and CD13 receptor expression was confirmed in malignant tissues.

Conclusions:

• The RGD-NGR heterodimer is a promising candidate for early PDAC detection.
• This tracer holds potential for screening high-risk populations for pancreatic cancer.